Industries > Pharma > Point of Care Diagnostics Market Report 2023-2033

Point of Care Diagnostics Market Report 2023-2033

Forecasts by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-abuse Testing, Fecal Occult Testing, Other), by Mode (Prescription-based, OTC), by Sample (Blood, Nasal and Oropharyngeal Swabs, Urine, Other), by Platform (Lateral Flow Assay, Dipstick, Microfluidics, Molecular Diagnostics, Immunoassay), by End-user (Clinics, Hospitals, Home Care Setting, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 03 January 2023
PAGES: 352
PRODUCT CODE: PHA1224
SUBMARKET: Diagnostics

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1224 Categories: , Tag:

The Point of Care Diagnostics Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Incidence of Target Conditions and Rising Number of CLIA Waived POC Tests Are Driving the Market Growth
Target conditions for POC testing are illnesses or disorders that require ongoing monitoring, such as diabetes, hemophilia, cancer, and cardiac problems. The adoption of POC testing equipment can therefore be attributed in large part to the rising incidence and prevalence of these illnesses. Diabetes is a serious, chronic disorder that can significantly affect people’s lives, wellbeing, and families all around the world. According to IDF, in 2021, there were 537 million diabetics worldwide between the ages of 20 and 79.

CLIA defines waived tests as straightforward laboratory investigations and procedures with a very low chance of producing an erroneous result. In addition to approving manufacturer petitions for test system waivers, the Food and Drug Administration (FDA) determines what standards testing must follow in terms of being simple and error prone. The Binx health io CT/NG test, a molecular platform used to detect STDs such as chlamydia and gonorrhea at the point of treatment, acquired a CLIA waiver from the US FDA in April 2021, according to a statement released at the time

Stringent and Time-Consuming Regulatory Policies Likely to Challenge Market Growth
The complicated FDA regulations and CLIA laboratory standards present manufacturers with some regulatory challenges despite the rising demand for POC equipment (for the premarket approval of POC testing kits). Manufacturers must provide performance data to the FDA for any new POC equipment to be approved in the United States. This should show that people and healthcare professionals can use these tools and get outcomes that are comparable to those of clinical laboratory tests. For in vitro diagnostic (IVD) equipment as opposed to non-IVD ones, the amount of examination is also rather exceptional. For instance, the FDA typically waits until the intended application, conditions for usage, target patient demographic, and test performance characteristics remain intact before re-examining approved prescription non-IVD devices for use in new situations. Though under this rule POC devices are not covered.

What Questions Should You Ask before Buying a Market Research Report?
• How is the point of care diagnostics market evolving?
• What is driving and restraining the point of care diagnostics market?
• How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each point of care diagnostics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading point of care diagnostics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the point of care diagnostics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of point of care diagnostics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the point of care diagnostics market?
• Where is the point of care diagnostics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the point of care diagnostics market today, and over the next 10 years:
• Our 352-page report provides 158 tables, 225 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the point of care diagnostics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising point of care diagnostics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product
• Glucose Monitoring
• Cardiometabolic Monitoring
• Infectious Disease Testing
• Coagulation Monitoring
• Pregnancy & Fertility Testing
• Tumor/Cancer Marker Testing
• Urinalysis Testing
• Cholesterol Testing
• Hematology Testing
• Drugs-of-abuse Testing
• Fecal Occult Testing
• Other POC Products

Mode
• Prescription-based
• OTC

Sample
• Blood
• Nasal and Oropharyngeal Swabs
• Urine
• Other

Platform
• Lateral Flow Assay
• Dipstick
• Microfluidics
• Molecular diagnostics
• Immunoassay

End User
• Clinics
• Hospitals
• Home Care Setting
• Others

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

Point of Care Diagnostics Market Report 2023-2033
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Point of Care Diagnostics Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott
• AccuBioTech Co., Ltd
• BD
• bioMerieux SA
• Chembio Diagnostics, Inc.
• Danaher
• EKF Diagnostics
• F. Hoffmann-La Roche Ltd
• Fluxergy
• LumiraDx
• Meridian Bioscience
• Nipro Europe Group Companies
• Nova Biomedical
• Orasure Technologies, Inc.
• PTS Diagnostics
• Qiagen
• Quidel Corporation
• Response Biomedical
• Sekisui Diagnostics
• Siemens Healthcare GmbH
• Spectral Medical Inc.
• Thermo Fisher Scientific Inc.
• Trinity Biotech Ireland
• Trividia Health, Inc.
• Werfen

Overall world revenue for Point of Care Diagnostics Market, 2023 to 2033 in terms of value the market will surpass US$43 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Point of care diagnostics Market, 2023 to 2033 report help you?
In summary, our 350+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Point of Care Diagnostics Market, 2023 to 2033 Market, with forecasts for product, mode, sample, platform, end user, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the Point of Care Diagnostics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Netherlands, China, India, Japan, Australia, South Korea, Brazil, GCC, and South Africa among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 25 of the major companies involved in the Point of Care Diagnostics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Point of Care Diagnostics Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Point of Care Diagnostics Market Report 2023-2033: Forecasts by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-abuse Testing, Fecal Occult Testing, Other), by Mode (Prescription-based, OTC), by Sample (Blood, Nasal and Oropharyngeal Swabs, Urine, Other), by Platform (Lateral Flow Assay, Dipstick, Microfluidics, Molecular Diagnostics, Immunoassay), by End-user (Clinics, Hospitals, Home Care Setting, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Point of Care Diagnostics Market Report 2023-2033

    Download sample pages

    Complete the form below to download your free sample pages for Point of Care Diagnostics Market Report 2023-2033

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ